Abstract The identification of potentially modifiable risk factors, such as body size, could allow for interventions that could help reduce the burden of contralateral breast cancer (CBC) among breast cancer survivors. Studies examining the relationship between body mass index (BMI) and CBC have yielded mixed results. From the population-based, case-control, Women's Environmental, Cancer and Radiation Epidemiology (WECARE) Study, we included 511 women with CBC (cases) and 999 women with unilateral breast cancer (controls) who had never used postmenopausal hormone therapy. Rate ratios (RR) and 95% confidence intervals (CI) were used to assess the relationship between BMI and CBC risk. No associations between BMI at first diagnosis or weight-change between first diagnosis and date of CBC diagnosis (or corresponding date in matched controls) and CBC risk were seen. However, obese (BMI C 30 kg/m 2 ) postmenopausal women with estrogen receptor (ER)-negative first primary tumors (n = 12 cases and 9 controls) were at an increased risk of CBC compared with normal weight women (BMI\ 25 kg/ m 2 ) (n = 43 cases and 98 controls) (RR = 5.64 (95% CI 1.76, 18.1)). No association between BMI and CBC risk was seen in premenopausal or postmenopausal women with ER-positive first primaries. Overall, BMI is not associated with CBC risk in this population of young breast cancer survivors. Our finding of an over five-fold higher risk of CBC in a small subgroup of obese postmenopausal women with an ER-negative first primary breast cancer is based on limited numbers and requires confirmation in a larger study.
Introduction
The relationship between body mass index (BMI) and risk of a first primary breast cancer is modulated by menopausal status. Most studies have found BMI to be inversely associated with premenopausal breast cancer risk [1] . Conversely, BMI has been positively associated with postmenopausal breast cancer risk [1] , especially among women with no history of postmenopausal hormone therapy (HT) use [2] [3] [4] . Studies have also shown that this relationship is limited to, or is more pronounced in, estrogen receptor (ER) and/or progesterone receptor (PR) positive tumors [5] [6] [7] . The association between BMI and breast cancer risk in postmenopausal women is largely mediated by endogenous hormone levels [8, 9] , and may be attributed to the aromatization of estrogen in peripheral adipose tissue. The inverse relationship seen in premenopausal women may be due to irregular menstrual cycles and anovulation associated with a high BMI [10] .
Studies examining the relationship between BMI and second primary breast cancer in the contralateral breast (CBC) have been mixed, with some showing no association [11] [12] [13] and others (including both premenopausal and postmenopausal women) showing a positive relationship [14] [15] [16] [17] [18] . Most known risk factors for CBC are not readily modifiable (i.e., family history, BRCA mutation status). BMI is a potentially modifiable risk factor, which could allow for targeted interventions that would help reduce the burden of CBC among breast cancer survivors. The Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study is a population-based case-control study comparing women with CBC (cases) to those with unilateral breast cancer (UBC) (controls). The objective of this analysis is to determine the association between BMI and CBC risk in premenopausal and postmenopausal women.
Materials and methods

Study population
The WECARE Study is a multi-center, population-based, case-control study where cases are women with asynchronous CBC and controls are women with UBC [19] . Each eligible case met the following criteria: (a) was diagnosed between 1/1/1985 and 12/31/2000 with UBC followed by a second primary, in situ or invasive, breast cancer in the contralateral breast, diagnosed at least 1 year after the first diagnosis; (b) resided in the same study reporting area for both diagnoses; (c) had no previous or intervening cancer diagnosis; (d) was under age 55 years at the time of diagnosis of the first primary breast cancer; (e) was alive at the time of contact; and (f) was able to provide informed written consent, complete the interview, and provide a blood sample. For the purpose of this study the ''at-risk'' interval was defined as starting 1 year after the first diagnosis and ending at reference date: i.e., date of the second breast cancer diagnosis in cases or the corresponding date in matched controls.
Eligible WECARE Study controls were: (a) diagnosed between 1/1/1985 and 12/31/1999 with UBC while residing in one of the study reporting areas; (b) residing on the reference date (defined as 1 year after first diagnosis plus the at-risk interval of matched cases) in the same cancer reporting area as when first diagnosed with breast cancer; (c) never diagnosed with any other cancer; (d) under age 55 years at the time of diagnosis; (e) able to provide informed written consent, complete the interview, and provide a blood sample; and (f) without prophylactic mastectomy of the contralateral breast. Two controls were individually matched to each case on year of birth (in 5-year strata), year of diagnosis (in 4-year strata), registry region, and race/ethnicity. The majority of women (92%) were identified as Caucasian based on registry data. Additionally, to improve statistical efficiency, cases and controls were counter-matched on registry-reported radiation exposure such that two members of the case-control triad had received radiation therapy for their index breast cancer [19] .
Across the five cancer registries, a total of 998 women with CBC and 2,112 women with UBC were identified as being eligible for the study as cases and controls, respectively. Of these, 708 cases (71%) and 1,399 controls (66%) completed the study interview and provided a blood sample. Reasons for non-participation of eligible women included, physician refusal (0.5% cases 1% controls), subject interview refusal (27% cases, 31% controls), and subject blood draw refusal (3% cases, 3% controls). The data collection protocol was approved by the institutional review board at each recruitment site and by the ethical committee system in Denmark.
Data collection
All participants in the WECARE Study were interviewed by telephone using a pre-tested, structured questionnaire. The questionnaire was designed to obtain information about events occurring before the diagnosis of the first primary breast cancer, as well as events that occurred within the at-risk period. The focus of the questionnaire was on known and suspected risk factors for breast cancer, including personal demographics, medical history, family and reproductive history, use of hormones, body size, smoking status, and alcohol intake. Additionally, medical records, pathology reports, and hospital charts were used to collect detailed treatment information (i.e., chemotherapy, hormonal therapy, and radiation therapy). Data on tumor characteristics of the first primary tumor (location in the breast, stage at diagnosis, ER and PR status, and histology) were also collected from the medical records.
Body size measures reported through the interview included height and weight at age 18 years as well as weight at first breast cancer diagnosis and at reference date. Sixteen women (3 cases and 13 controls) were missing information for height and/or weight at age 18 years, 4 (1 case and 3 controls) at first diagnosis and 1 (control) at reference date, and were therefore excluded from the analysis. Additionally, women with an implausibly high ([53 kg/m 2 ) (1 control at first diagnosis, 1 case at reference date) or low (\16 kg/m 2 ) (12 cases and 23 controls at age 18 years, 3 cases and 2 controls at first diagnosis, and 2 cases at reference date) BMI were excluded. Four women (1 case and 3 controls) were excluded because of weight values that were outliers (\36.3 kg and [136 kg).
Statistical analysis
Rate ratios (RR) and 95% confidence intervals (CI) were used to assess the relationship between weight and BMI and risk of CBC. These were obtained using conditional logistic regression adjusting for known risk factors for breast cancer, including age at diagnosis (continuous), age at menarche (\13, C13), number of full-term pregnancies (nulliparous, 1-3, C4), family history (yes, no, adopted), histology (lobular, other), stage (local, regional), chemotherapy (yes, no), hormonal treatment (yes, no), and radiation therapy (yes, no). Hormonal breast cancer treatments included tamoxifen, raloxifene, toremifene citrate, anastrozole, letrozole, exemestane, aminoglutethimide, goserelin acetate, leuprorelin, fulvestrant, and megestrol acetate. A log-weight covariate was included in the model to account for the sampling probability of the countermatching [19] . World Health Organization (WHO) categories of BMI were used to classify women as normal weight (BMI \ 25 kg/m 2 ), overweight (25-30 kg/m 2 ) or obese (C30 kg/m 2 ). Based on the results of prior studies of first primary breast cancer, the analysis was stratified by menopausal status at the start of the at-risk period (1 year after first breast cancer diagnosis). Menopausal status was determined by comparing the date or age a women last reported menstruating to the date of first diagnosis. If a woman reported that she was still menstruating up to 1 year after first diagnosis (the start of the at-risk period) or was pregnant, she was classified as premenopausal. Women were also asked to indicate all reasons why they stopped menstruating, including natural menopause, surgery (bilateral oophorectomy and/or hysterectomy) or treatment (chemotherapy, radiation, and tamoxifen).
All analyses were conducted excluding women who had reported HT use any time before reference date (173 cases and 352 controls), and those with unknown menopausal status (1 case and 2 controls), leaving 1510 women (511 CBC cases and 999 UBC controls) for this analysis. Results are presented stratified by menopausal status and by ERstatus of the first primary tumor with P-values for a linear trend across BMI categories. Table 1 shows selected characteristics of the eligible WECARE Study population. Cases and controls were similar on all matching characteristics with a median age at first diagnosis of 45 years and a median age at reference Breast Cancer Res Treat (2012) 131:571-580 573 Excludes women with missing height and/or weight (n = 21), those who were outliers for BMI (n = 44) or weight (n = 4) at either age 18, first diagnosis or reference date, women who reported use of postmenopausal hormone therapy at any time prior to reference date (n = 525) and women with missing information on menopausal status (n = 3 date (age at second breast cancer diagnosis in cases) of 49 years. The average at-risk period was 4 years. There were 852 women (56.4%) who reported that they were postmenopausal at the start of the at-risk period. Of these, 23.8% indicated that they had experienced natural menopause, 17.8% attributed menopause to surgeries (including bilateral oophorectomy and/or hysterectomy), and 57.7% attributed menopause to treatment (chemotherapy, radiation, tamoxifen, and aromatase inhibitor) of their first breast cancer. Information on reason for menopause was missing for approximately 1% of women. Overall, no association was observed between CBC risk and BMI at first diagnosis or weight-change between first diagnosis and reference date, for premenopausal or postmenopausal women (Table 2 ). There was also no association between BMI at age 18 years or at reference date (data not shown). Table 3 shows the relationship between BMI and CBC risk stratified by menopausal status and ER-status of the first primary tumor. Obese (BMI C 30 kg/m 2 ) postmenopausal women with ER-negative first primary tumors had an over five-fold higher risk of developing a second primary in the contralateral breast compared with normal weight (BMI \ 25 kg/m 2 ) women with ER-negative first tumors (RR = 5.64, 95% CI 1.76, 18.1). CBC risk was also elevated in obese premenopausal women with ER-negative first tumors, but this association did not reach statistical significance (RR = 2.68, 95% CI 0.79, 9.11). An increase in risk was also seen when pre-and post-menopausal women with ER-negative first primaries were combined (RR = 3.31, 95% CI 1.39, 7.86). In all instances, the trend across BMI categories was not statistically significant. No association between BMI and CBC risk was seen in women with ER-positive first tumors, regardless of menopausal status. Results did not differ when the 203 women who underwent natural menopause were excluded from the analysis (data not shown). We had an insufficient number of women to look at weight-change between first diagnosis and reference date stratified by both menopausal status and ER-status of the first tumor. Although we were able to evaluate the impact of ERstatus of the first tumor on the relationship between BMI and CBC risk, data on the ER-status of the second primary was insufficient for analysis. Of the 139 CBC cases diagnosed with ER-negative first tumors, information on the ER-status of the second primary was only available for 88 (63.3%) women. Of these women 52 (59.1%) were diagnosed with an ER-negative second primary. The ER-status of the second primary was available for 186 (76.2%) cases diagnosed with an ER-positive first tumor, of whom only 12.9% were diagnosed with ER-negative second primaries.
Results
Discussion
BMI at age 18 years, first diagnosis, and reference date (date of second breast cancer diagnosis for cases and corresponding date in controls) was not associated with CBC risk in this population of young breast cancer survivors. Weight-change between first diagnosis and reference date also was not associated with risk, although the majority of women in our study maintained a relatively stable weight between first diagnosis and reference date. On average this time period was 5 years long, but could have been as short as 1 year, limiting our ability to fully examine the relationship between weight-change and CBC risk.
A small group of obese, postmenopausal women with ER-negative first primary tumors was found to have more than a five-fold greater risk of developing a second primary in the contralateral breast, than normal weight women with ER-negative first tumors (RR = 5.6). However, the trend across BMI categories was not statistically significant. CBC risk was also elevated (RR = 2.7) in obese premenopausal women with ER-negative first tumors, although the association was not statistically significant. When pre-and post-menopausal women with ER-negative first primaries were combined, again a significant increase in risk was seen in obese women (RR = 3.3). No association between BMI and CBC risk was seen in premenopausal or postmenopausal women with ER-positive first primaries. We were unable to investigate the relationship between BMI and CBC risk by the ER-status of the second primary because, as a result of missing information on receptor status, the sample size was too small for analysis. Few studies have explored the association between BMI and CBC risk and the results have been inconsistent [11] [12] [13] [14] [15] [16] [17] [18] 20] . Even fewer studies have examined whether hormone receptor status of the first primary tumor influenced this relationship [15, 16, 18] . Our results for ER-negative first breast cancers are consistent with those from the National Surgical Adjuvant Breast and Bowel Project B-14 Trial, which found that among women with node-negative ER-negative first tumors, those women who were obese and postmenopausal had a two-fold greater risk of CBC than normal weight postmenopausal women [16] . Unlike the results of this study, they also found an association between BMI and CBC risk in premenopausal women [16] . Their results for ER-positive first breast cancers also differed from ours. They found that both premenopausal and postmenopausal obese women with node-negative ERpositive first tumors had a greater risk of CBC than normal weight women (HR = 1.58, 95% CI 1.10, 2.25) [15] . In another population-based case-control study of women with an ER-positive first tumor, obese women had a higher risk of CBC than normal weight women (OR = 1.5, 95% CI 1.0, 2.1) [18] .
Some studies have suggested that the impact of BMI on postmenopausal first primary breast cancer risk maybe limited to ER-positive tumors [5] [6] [7] 21] . This has largely been attributed to the positive association between endogenous estrogen levels and BMI [9] . Estrogens play a central role in breast cancer etiology and elevated levels of circulating estrogens are associated with increased breast cancer risk in postmenopausal women [22] . Conversion of androgens (testosterone and androstenedione) to estrogens (estradiol (E2) and estrone (E1), respectively) by aromatase in peripheral adipose tissues is the primary source of estrogens in postmenopausal women.
Unlike other studies [15, 18] , we did not find an association between BMI and CBC risk in women with ERpositive first tumors. If the impact of BMI on CBC risk is mediated through its effects on endogenous hormones, it may be attenuated by the use of hormonal treatments (tamoxifen and aromatase inhibitors) for ER-positive first primaries, as tamoxifen is known to be associated with a lower risk of developing CBC [23] . Thus the strong impact of tamoxifen on subsequent CBC risk may overshadow any adverse effect that BMI may have on risk in these women.
Although we adjusted for hormonal treatments in this analysis, we were unable to conduct the analysis excluding women who had received tamoxifen treatment due to sample size limitations.
The strengths of this study include the populationbased design, large study population, detailed questionnaire data, and confirmation of interview data, where possible, by medical records. Limitations include the lack of data on physical activity, limited number of women with ER-negative first breast cancers, incomplete data on ER-status of the second primary breast cancer in cases, and insufficient sample size to examine the relationship between BMI and CBC risk after excluding women who received hormonal treatment. The short interval between first diagnosis and CBC prevented assessing the impact of long-term weight-change on risk or of evaluating whether BMI might affect CBC risk at longer intervals as found by Majed et al. [20] .
In this population of young breast cancer survivors, BMI at first diagnosis did not influence CBC risk overall. Our finding of an over five-fold higher risk of CBC in obese postmenopausal women with an ER-negative first primary breast cancer is based on small numbers and requires confirmation in other studies. The potential benefit of weight-loss on CBC risk in women with ER-negative first tumors is yet to be established. These results add to the limited body of literature describing non-treatment related risk factors for CBC. If our result for ER-negative breast cancer is confirmed, it would have important implications for the clinical management of ER-negative breast cancers.
